# US 6,730,682 B2 · Heterocycle carboxamides as antiviral agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,682 B2
- Document ID: US6730682B2
- Status: Granted
- Kind: B2
- Application number: 09/887,620
- Filed: 2001-06-22
- Published: 2002-02-14
- Granted: 2004-05-04
- Earliest claimed: 2000-07-12
- Assignees: Pharmacia & Upjohn Company
- Inventors: Mark E. Schnute; Valerie A. Vaillancourt
- Web page: https://patentgrep.com/patent/US6730682B2

## CPC

- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 217/14: other than aralkyl radicals
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

## Claims

### Claim 1

A compound of formula I,
or a pharmaceutically acceptable salt thereof wherein
X is Cl, Br, F, CN or NO2;
G is
(a) C1-7alkyl which partially unsaturated and is substituted by hydroxy, or
(b) C1-4alkyl substituted by NR1R2 or 4-tetrahydropyran;
R1 is C2-7alkyl substituted by hydroxy, C1-4alkoxy, aryl, or heteroaryl;
R2 is hydrogen or C1-7alkyl; or
R1 and R2 together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C1-7alkyl;
W is a formula W1.20, W3.4, or W3.12;
R6is
(a) H,
(b) halo,
(c) aryl,
(d) het,
(e) OR12,
(f) SR12,
(g) C1-7alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR12, SR12, NR10R11, aryl, halo, C3-8cycloalkyl optionally substituted by OR12, or het attached through a carbon atom,
(h) NR10R11,
(i) C3-8cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR12, SR12, or NR10R11,
(j) (C═O)R9,
(k) S(O)mR9,
(l) (C═O)OR2,
(m) NHSO2R9,
(n) nitro, or
(o) cyano;
R7 is
(a) H,
(b) C1-7alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR12, SR12, NR10R11, or halo,
(c) C3-8cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR12, SR12, or NR10R11,
(d) aryl, or
(e) het;
R8 is
(a) H,
(b) C1-7alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR12, SR12, NR10R11, or halo,
(c) OR12, or
(d) SR12;
R9 is
(a) C1-7alkyl,
(b) NR10R11,
(c) aryl, or
(d) het, wherein said het is bound through a carbon atom;
R10 and R11 are independently
(a) H,
(b) aryl,
(c) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR2R2, CO2R2, het, aryl, cyano, or halo,
(d) C2-7alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR2R2, OR2, or SR2,
(e) C3-8cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR2, SR2, or NR2R2, or
(f) R10 and R11 together with the nitrogen to which they are attached form a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring which may contain additional 1 or 2 heteroatoms selected from oxygen, sulfur, or nitrogen;
R12 is
(a) H,
(b) aryl,
(c) het
(d) C1-7alkyl optionally substituted by aryl, het, or halogen,
(e) C2-7alkyl substituted by OR2, SR2, or NR2R2, or
(f) C3-8cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR2, SR2, or NR2R2;
each m is independently 1 or 2;
aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR2R2, CO2R2, CF3, C1-6alkoxy, and C1-6 alkyl which maybe further substituted by one to three SR2, NR2R2, OR2, or CO2R2 groups;
het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, C2R2, CF3, C1-6alkoxy, oxo, oxime, and C1-6 alkyl which may be further substituted by one to three SR2, NR2R2, OR2, or CO2R2 groups;
halo or halogen is F, Cl, Br, I;
1 represents the point of attachment between W and G; and
2 represents the point of attachment between W and the carbonyl group of formula I.

### Claim 2 (depends on 1)

A compound of claim 1 wherein X is Cl.

### Claim 3 (depends on 1)

A compound of claim 1 wherein G is 4-morpholinylmethyl.

### Claim 4 (depends on 1)

A compound of claim 1 wherein G is 3-hydroxy-1-propynyl.

### Claim 5 (depends on 1)

A compound of claim 1 wherein G is tetrahydro-2H-pyran-4-ylmethyl.

### Claim 6 (depends on 1)

A compound of claim 1 which is N-(4-chlorobenzyl)-8hydroxy-2-(3hydroxy-1-propynyl)pyrido[3,2-d]pyrimidine-7carboxamide, or N-(4-chlorobenzyl)8-hydroxy-2-(4-morpholinylmethyl)pyrido[3,2-d]pyrimidine-7-carboxamide.

### Claim 7 (depends on 1)

A method of treating a herpes viral infection comprising administering to a mammal in need of such treatment a compound of claim 1.

### Claim 8 (depends on 7)

The method of claim 7 wherein said mammal is a human.

### Claim 9 (depends on 7)

The method of claim 7 wherein said mammal is a food animal or companion animal.

### Claim 10 (depends on 7)

The method of claim 7 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type, 6, 7, or 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.

### Claim 11 (depends on 7)

The method of claim 7 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.

### Claim 12 (depends on 7)

The method of claim 7 wherein the amount administered is from about 0.1 to about 300 mg/kg of body weight.

### Claim 13 (depends on 7)

The method claim 7 wherein the amount administered is from about 1 to about 30 mg/kg of body weight.

### Claim 14 (depends on 7)

The method of claim 7 wherein the compound is administered parenterally, topically, intravaginally, orally, or rectally.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
